Annika Brakebill, A. Mark Fendrick, MD, and Jeffrey T. Kullgren, MD, MS, MPH
These key steps are ones health sector stakeholders should take to help patients and clinicians use pricing information to inform health decision making.
AMA J Ethics. 2022;24(11):E1034-1039. doi:
10.1001/amajethics.2022.1034.
Jing Li, PhD, Robert Tyler Braun, PhD, Sophia Kakarala, and Holly G. Prigerson, PhD
For dying patients and their loved ones to make informed decisions, physicians must share adequate information about prognoses, prospective benefits and harms of specific interventions, and costs.
AMA J Ethics. 2022;24(11):E1040-1048. doi:
10.1001/amajethics.2022.1040.
Fragmentation in US health care delivery streams and shortcomings in formal quality measures mean that transparency could be more useful to policymakers and regulators than patients.
AMA J Ethics. 2022;24(11):E1075-1082. doi:
10.1001/amajethics.2022.1075.
Sarosh Nagar, Leah Z. Rand, PhD, and Aaron S. Kesselheim, MD, JD, MPH
This article analyzes differences in prescription drug pricing transparency practices among 3 Organisation of Economic Co-operation and Development member nations.
AMA J Ethics. 2022;24(11):E1083-1090. doi:
10.1001/amajethics.2022.1083.
D. Brendan Johnson, MTS and C. Phifer Nicholson Jr
Meditation on images of corporeal suffering were once part of a “spiritual ordeal” that can still provoke a kind of transformation key to health professionalism.
AMA J Ethics. 2022;24(12):E1172-1180. doi:
10.1001/amajethics.2022.1172.
Osler’s contributions to the philosophy and practice of medicine foreground characteristics of a compassionate caregiver, including imperturbability and equanimity.
AMA J Ethics. 2022;24(12):E1166-1171. doi:
10.1001/amajethics.2022.1166.
Dr Jing Li joins Ethics Talk to discuss her article, coauthored with Dr Robert Tyler Braun, Sophia Kakarala, and Dr Holly G. Prigerson: “How Should Cost-Informed Goals of Care Decisions Be Facilitated at Life’s End?”